Evidence map›Paper›PMID 39970298›Full record

ArticleNucleic acids research2025

XRCC1 mediates PARP1- and PAR-dependent recruitment of PARP2 to DNA damage sites.

Xiaohui Lin, Kay Sze Karina Leung, Kaitlynn F Wolfe, Nicolas Call, Seema Khattri Bhandari, Xiaoyu Huang, Brian J Lee, Alan E Tomkinson, Shan Zha

Abstract read
In one paragraph

Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Xiaohui LinInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY 10032, United States.
Kay Sze Karina LeungColumbia College, Columbia University, New York, NY 10027, United States.
Kaitlynn F WolfeColumbia College, Columbia University, New York, NY 10027, United States.
Nicolas CallDepartment of Internal Medicine and Molecular Genetics & Microbiology, University of New Mexico Comprehensive Cancer Center, University of New Mexico Health Sciences Center, 1 University of New Mexico, Albuquerque, NM 87131, United States.
Seema Khattri BhandariDepartment of Internal Medicine and Molecular Genetics & Microbiology, University of New Mexico Comprehensive Cancer Center, University of New Mexico Health Sciences Center, 1 University of New Mexico, Albuquerque, NM 87131, United States.
Xiaoyu HuangInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY 10032, United States.
Brian J LeeInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY 10032, United States.
Alan E TomkinsonDepartment of Internal Medicine and Molecular Genetics & Microbiology, University of New Mexico Comprehensive Cancer Center, University of New Mexico Health Sciences Center, 1 University of New Mexico, Albuquerque, NM 87131, United States.ORCID 0000-0002-2671-1711
Shan ZhaInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY 10032, United States.ORCID 0000-0002-6568-1818

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3M
Transcription-Coupled & Replication-Associated Excision RepairP01CA092584 · NCI · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI WALTER J. CHAZIN · 2001 to 2026
$89.6M
The Role of CTIP in Lymphocyte Development and LymphomagenesisP01CA174653 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI RABADAN, RAUL · 2014 to 2024
$17.6M
The role of ATM in the suppression of lymphoid malignancyR01CA158073 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Shan Zha · 2011 to 2026
$5.7M
The role of HPF1 in radiation and genotoxic cancer therapyR01CA293675 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Shan Zha · 2024 to 2026
$3.0M
The non-catalytic function of PARP2 in DNA repair and cancer therapyR01CA271595 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Shan Zha · 2022 to 2026
$2.9M
The role of DNA-PKcs in DNA repair, lymphocyte development, RNA metabolism and tumor suppressionR01CA275184 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Shan Zha · 2022 to 2026
$2.7M
DNA-PKCS Phosphorylation in DNA Repair and Chromosomal TranslocationsR01CA184187 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ZHA, SHAN · 2015 to 2019
$1.8M
The catalytic and non-catalytic functions of PARP1 in cancer biologyR01CA226852 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ZHA, SHAN · 2018 to 2022
$1.8M
Targeting DNA Ligase I in Ovarian CancerR01CA276837 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Alan E Tomkinson · 2023 to 2026
$1.5M
Herbert Irving Comprehensive Cancer Center (HICCC)NCI NIH HHS P01 CA092584NCI NIH HHS P01 CA174653NCI NIH HHS P30 CA013696NCI NIH HHS P30CA013696NCI NIH HHS R01 CA158073NCI NIH HHS R01 CA184187NCI NIH HHS R01 CA226852NCI NIH HHS R01 CA271595NCI NIH HHS R01 CA275184NCI NIH HHS R01 CA276837NCI NIH HHS R01 CA293675NIHNIH HHS CA271595
6 · The paper itself

Abstract

Poly-ADP-ribose polymerases 1 and 2 (PARP1 and 2) are critical sensors of DNA-strand breaks and targets for cancer therapy. Upon DNA damage, PARP1 and 2 synthesize poly-ADP-ribose (PAR) chains on themselves and other substrates, facilitating DNA single-strand break repair by recruiting PAR-binding DNA repair factors, including X-ray repair cross-complementing group 1 (XRCC1) and aprataxin and polynucleotide kinase phosphatase-like factor (APLF). While diverse DNA lesions activate PARP1, PARP2 is selectively activated by 5' phosphorylated nicks. They function independently and compensate for each other. Previous studies suggest that PARP1 and its PAR chains act upstream to recruit PARP2 to DNA damage sites. Here, we report that the scaffold protein XRCC1 mediates PARP1- and PAR-dependent recruitment of PARP2 to damage sites. XRCC1-deficiency causes hyperactivation of PARP1 while attenuating micro-irradiation-induced PARP2 foci. Mechanistically, the BRCT1 domain of XRCC1 binds to PAR, while its BRCT2 domain interacts with the PARP2 catalytic domain independently of the PARP2 enzymatic activity and the LIG3 BRCT domain via residues D575 and Y576. This mode of PARP2 enrichment is important for the recruitment of certain PAR-binding proteins, such as APLF, but dispensable for others, such as the XRCC1-BRCT1 domain. These findings highlight the distinct role of PARP1 and PARP2 in PAR synthesis and uncover unexpected hierarchical roles of PARP1 and XRCC1 upstream of PARP2.

Indexed as

DNA DamagePoly Adenosine Diphosphate RibosePoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) PolymerasesX-ray Repair Cross Complementing Protein 1AnimalsDNA-Binding ProteinsDNA RepairHumansMiceDNA-Binding ProteinsPARP1 protein, humanParp1 protein, mousePARP2 protein, humanParp2 protein, mousePoly Adenosine Diphosphate RibosePoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) PolymerasesX-ray Repair Cross Complementing Protein 1XRCC1 protein, humanXrcc1 protein, mouse

Identifiers

PMID39970298
PMCPMC11838041

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.